These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 29631750

  • 21. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.
    Koch M, Wiech T, Marget M, Peine S, Thude H, Achilles EG, Fischer L, Lehnhardt A, Thaiss F, Nashan B.
    Clin Transplant; 2015 Nov; 29(11):1021-8. PubMed ID: 26333844
    [Abstract] [Full Text] [Related]

  • 22. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience.
    Habicht A, Bröker V, Blume C, Lorenzen J, Schiffer M, Richter N, Klempnauer J, Haller H, Lehner F, Schwarz A.
    Nephrol Dial Transplant; 2011 Dec; 26(12):4124-31. PubMed ID: 21622990
    [Abstract] [Full Text] [Related]

  • 23. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B, Tedesco-Silva H, Ettenger R, Christian M, Bjerre A, Dello Strologo L, Marks SD, Pape L, Veldandi U, Lopez P, Cousin M, Pandey P, Meier M.
    Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
    [Abstract] [Full Text] [Related]

  • 24. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
    Traitanon O, Mathew JM, Shetty A, Bontha SV, Maluf DG, El Kassis Y, Park SH, Han J, Ansari MJ, Leventhal JR, Mas V, Gallon L.
    PLoS One; 2019 Jan; 14(5):e0216300. PubMed ID: 31136582
    [Abstract] [Full Text] [Related]

  • 25. B cells and immunoglobulin in ABO-incompatible renal transplant patients receiving rituximab and double filtration plasmapheresis.
    Tsai MK, Wu MS, Yang CY, Lee CY, Yeh CC, Hu RH, Lee PH, Lai HS.
    J Formos Med Assoc; 2015 Apr; 114(4):353-8. PubMed ID: 25839769
    [Abstract] [Full Text] [Related]

  • 26. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 27. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP, Esmeraldo RM, Pinto CM, Sandes-Freitas TV, Felipe C, Lobo CF, Viana L, Mansur J, Stopa S, Santos DWC, Grenzi PC, Aguiar WF, Tedesco-Silva H, Pestana JOM.
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 29. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 Mar; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 30. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

  • 31. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K, Hyodo Y, Aikawa A.
    Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
    [Abstract] [Full Text] [Related]

  • 32. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R, Unagami K, Kakuta Y, Furusawa M, Okumi M, Azuma H, Ishida H, Tanabe K.
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [Abstract] [Full Text] [Related]

  • 33. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S, Hwang E, Park S, Park U, Kim H, Cho W.
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [Abstract] [Full Text] [Related]

  • 34. Long-term desensitization for ABO-incompatible living related kidney transplantation recipients with high refractory and rebound anti-blood type antibody: case report.
    Nishimura H, Yamada Y, Hisano S, Mitsuke A, Tatarano S, Gotanda T, Hayami H, Nakagawa M, Enokida H.
    BMC Nephrol; 2018 Oct 05; 19(1):254. PubMed ID: 30290778
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation.
    Yoshimura N, Nakao T, Nakamura T, Harada S, Koshino K, Suzuki T, Ito T, Nobori S, Ushigome H.
    Transplant Proc; 2016 Apr 05; 48(3):786-9. PubMed ID: 27234736
    [Abstract] [Full Text] [Related]

  • 36. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
    Favi E, Spagnoletti G, Salerno MP, Pedroso JA, Romagnoli J, Citterio F.
    Clin Transplant; 2013 Apr 05; 27(4):E359-67. PubMed ID: 23710603
    [Abstract] [Full Text] [Related]

  • 37. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN, Felipe CR, Cristelli M, Viana L, Mansur J, de Paula M, Wagner D, de Marco R, Gerbase-DeLima M, Proença H, Aguiar W, Medina-Pestana J, Tedesco-Silva Junior H.
    Transpl Int; 2019 Nov 05; 32(11):1127-1143. PubMed ID: 31278785
    [Abstract] [Full Text] [Related]

  • 38. Distribution of Anti-ABO Immunoglobulin G Subclass and C1q Antibody in ABO-incompatible Kidney Transplantation.
    Lee KH, Won DI, Yook JM, Kim KY, Park SM, Park JH, Lee ES, Lim JH, Jung HY, Choi JY, Park SH, Kim CD, Kim YL, Kim HK, Huh S, Cho JH.
    Transplant Proc; 2018 May 05; 50(4):1063-1067. PubMed ID: 29731066
    [Abstract] [Full Text] [Related]

  • 39. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 40. Excellent outcome of ABO-incompatible living kidney transplantation under pretransplantation immunosuppression with tacrolimus, mycophenolate mofetil, and steroid.
    Tanabe K, Tokumoto T, Ishida H, Ishikawa N, Miyamoto N, Kondo T, Shimmura H, Setoguchi K, Toma H.
    Transplant Proc; 2004 Sep 20; 36(7):2175-7. PubMed ID: 15518791
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.